Technology | December 22, 2014

AliveCor Launches Third Generation Heart Monitor Smartphone App System

New compact medical grade mobile ECG device is 50-percent thinner, 40-percent lighter

AliveCor Heart Monitor, third generation, ECG, atrial fibrillation, AF

December 22, 2014 — AliveCor Inc. announced the launch of its third-generation AliveCor Heart Monitor. Now users have the ability to identify and manage heart conditions with a U.S. Food and Drug Administration (FDA)-cleared electrocardiogram (ECG) monitor, anywhere and at anytime. The third-generation device is now 50-percent thinner and 40-percent lighter and was designed from first-hand customer feedback and in collaboration with global design firm IDEO.

Atrial fibrillation (AF) continues to be the most common heart rhythm disturbance, affecting more than 140 million people worldwide. AliveCor is focused on helping those with diagnosed and undiagnosed heart conditions, by providing patients and caregivers a tool to detect and manage heart conditions.

Users of the AliveCor Heart Monitor are recording 130,000 ECGs per month and actively tracking over 10,000 symptoms, medications and activities that may be affecting their health. In the two months since the AF Detector algorithm was launched, AliveCor has detected more than 20,000 incidents of AF in more than 30 percent of users recording ECGs.

Detecting AF is the first step to initiating a treatment plan to reduce stroke risk, as people with AF are five times more likely to suffer a stroke than those without the condition. Additionally, users continue to engage with the product over time: 70 percent are regularly using the device after six months.

“I used to get frustrated when I would experience what I thought was an AF episode but couldn’t get to the doctor’s office fast enough to confirm my instincts,” said Terry Reilly, AliveCor patient since 2012. “With the AliveCor Heart Monitor, I am relieved to have an easy-to-use tool at my fingertips that can instantly detect my AF episodes when they happen.”

“The AliveCor Heart Monitor leads to results that I can use to manage my patients remotely, a trend that is here to stay," said Jeffrey Olgin, M.D., chief, division of cardiology co-director, Heart and Vascular Center at the University of California San Francisco. “Seeing my patients’ ECG results in real-time is the next best thing to having them in my office when the event takes place.” 

“Big data and personalized medicine are revolutionizing the delivery of care and have the potential to disrupt the way we think about healthcare. We are excited to be on the forefront of helping patients manage their cardiac health,” said Euan Thomson, president and chief executive officer at AliveCor. “The newest generation of the Heart Monitor confirms AliveCor’s ongoing commitment to help stop the unnecessary loss of life and healthcare costs driven by undiagnosed and under-managed heart arrhythmias that lead to potentially life-threatening conditions like strokes.”

For more information: www.alivecor.com

Related Content

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension| September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init